2024 FDA approvals exceed average number but have lower sales projections A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are FDA approvals February 2026 Innovative Biologics Expected Biologic Drug Approvals in 2026